 Lipoxygenase Inhibitors
"Lipoxygenase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that bind to and inhibit that enzymatic activity of LIPOXYGENASES. Included under this category are inhibitors that are specific for lipoxygenase subtypes and act to reduce the production of LEUKOTRIENES.
| Descriptor ID |
D016859
|
| MeSH Number(s) |
D27.505.519.389.480
|
| Concept/Terms |
Arachidonate 15-Lipoxygenase Inhibitors- Arachidonate 15-Lipoxygenase Inhibitors
- 15-Lipoxygenase Inhibitors, Arachidonate
- Arachidonate 15 Lipoxygenase Inhibitors
- Inhibitors, Arachidonate 15-Lipoxygenase
- 15-Lipoxygenase Inhibitors
- 15 Lipoxygenase Inhibitors
- Inhibitors, 15-Lipoxygenase
Arachidonate 5-Lipoxygenase Inhibitors- Arachidonate 5-Lipoxygenase Inhibitors
- 5-Lipoxygenase Inhibitors, Arachidonate
- Arachidonate 5 Lipoxygenase Inhibitors
- Inhibitors, Arachidonate 5-Lipoxygenase
- 5-Lipoxygenase Inhibitors
- 5 Lipoxygenase Inhibitors
- Inhibitors, 5-Lipoxygenase
Arachidonate 12-Lipoxygenase Inhibitors- Arachidonate 12-Lipoxygenase Inhibitors
- 12-Lipoxygenase Inhibitors, Arachidonate
- Arachidonate 12 Lipoxygenase Inhibitors
- Inhibitors, Arachidonate 12-Lipoxygenase
- 12-Lipoxygenase Inhibitors
- 12 Lipoxygenase Inhibitors
- Inhibitors, 12-Lipoxygenase
|
Below are MeSH descriptors whose meaning is more general than "Lipoxygenase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Lipoxygenase Inhibitors".
This graph shows the total number of publications written about "Lipoxygenase Inhibitors" by people in this website by year, and whether "Lipoxygenase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2019 | 2 | 0 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipoxygenase Inhibitors" by people in Profiles.
-
Montford JR, Bauer C, Rahkola J, Reisz JA, Floyd D, Hopp K, Soranno DE, Klawitter J, Weiser-Evans MCM, Nemenoff R, Faubel S, Furgeson SB. 15-Lipoxygenase worsens renal fibrosis, inflammation, and metabolism in a murine model of ureteral obstruction. Am J Physiol Renal Physiol. 2022 01 01; 322(1):F105-F119.
-
Thalanayar Muthukrishnan P, Nouraie M, Parikh A, Holguin F. Zileuton use and phenotypic features in asthma. Pulm Pharmacol Ther. 2020 02; 60:101872.
-
Montford JR, Bauer C, Dobrinskikh E, Hopp K, Levi M, Weiser-Evans M, Nemenoff R, Furgeson SB. Inhibition of 5-lipoxygenase decreases renal fibrosis and progression of chronic kidney disease. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F732-F742.
-
Rank MA, Liesinger JT, Branda ME, Gionfriddo MR, Schatz M, Zeiger RS, Shah ND. Comparative safety and costs of stepping down asthma medications in patients with controlled asthma. J Allergy Clin Immunol. 2016 05; 137(5):1373-1379.e3.
-
Takahashi H, Riether D, Bartolozzi A, Bosanac T, Berger V, Binetti R, Broadwater J, Chen Z, Crux R, De Lombaert S, Dave R, Dines JA, Fadra-Khan T, Flegg A, Garrigou M, Hao MH, Huber J, Hutzler JM, Kerr S, Kotey A, Liu W, Lo HY, Loke PL, Mahaney PE, Morwick TM, Napier S, Olague A, Pack E, Padyana AK, Thomson DS, Tye H, Wu L, Zindell RM, Abeywardane A, Simpson T. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915). J Med Chem. 2015 Feb 26; 58(4):1669-90.
-
Corser-Jensen CE, Goodell DJ, Freund RK, Serbedzija P, Murphy RC, Farias SE, Dell'Acqua ML, Frey LC, Serkova N, Heidenreich KA. Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits. Exp Neurol. 2014 Jun; 256:7-16.
-
Pian P, Labovitz E, Hoffman K, Clavijo CF, Rzasa Lynn R, Galinkin JL, Vinks AA, Malik P, Christians U. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Oct 15; 937:79-83.
-
Eun JC, Moore EE, Mauchley DC, Johnson CA, Meng X, Banerjee A, Wohlauer MV, Zarini S, Gij?n MA, Murphy RC. The 5-lipoxygenase pathway is required for acute lung injury following hemorrhagic shock. Shock. 2012 Jun; 37(6):599-604.
-
Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Harnden SM, Kim V, Marchetti N, Martinez FJ, McEvoy CE, Niewoehner DE, Reilly JJ, Rice K, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Lazarus SC. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 2011 Feb; 8(1):21-9.
-
Zarbock A, Distasi MR, Smith E, Sanders JM, Kronke G, Harry BL, von Vietinghoff S, Buscher K, Nadler JL, Ley K. Improved survival and reduced vascular permeability by eliminating or blocking 12/15-lipoxygenase in mouse models of acute lung injury (ALI). J Immunol. 2009 Oct 01; 183(7):4715-22.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|